Low-Contrast Letter Acuity Detects Visual Function Improvement in Phase 3 Relapsing MS Trials of Natalizumab

Update Item Information
Identifier 20100308_nanos_sciplatform_05.pdf
Title Low-Contrast Letter Acuity Detects Visual Function Improvement in Phase 3 Relapsing MS Trials of Natalizumab
Creator Laura J. Balcer, MD, Professor, Department of Neurology, NYU Langone; Steven L. Galetta, MD, NYU Langone; Polman, Chris; Rudick, Richard; Munschauer, Frederick; Calabresi, Peter; Eric R. Eggenberger, DO, Mayo Clinic; Zhang, Annie; Kim, Richard
Subject multiple sclerosis (MS); visual function; low-contrast letter acuity; natalizumab
Description In the AFFIRM trial, natalizumab reduced sustained visual loss by low-contrast letter acuity (LCA), but not highcontrast visual acuity (HCA). Natalizumab was associated with improvements in disability and quality of life; we determined whether similar improvements could be demonstrated for vision.
Date 2010-03-08
Language eng
Format application/pdf
Format Creation application/pdf
Type Text
Source 2010 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of NANOS 2010: Scientific Platform Presentations
Collection Neuro-ophthalmology Virtual Education Library: NOVEL http://NOVEL.utah.edu
Publisher Spencer S. Eccles Health Sciences Library, University of Utah
Holding Institution North American Neuro-Ophthalmology Association. NANOS Executive Office 5841 Cedar Lake Road, Suite 204, Minneapolis, MN 55416
Rights Management Copyright 2010. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright
ARK ark:/87278/s6sr25sc
Context URL The NANOS Annual Meeting Neuro-Ophthalmology Collection: https://novel.utah.edu/collection/NAM/toc/
Contributor Secondary Nicholas Volpe, MD; Janine Johnston, MD, FRCP(C)
Setname ehsl_novel_nam
ID 180642
Reference URL https://collections.lib.utah.edu/ark:/87278/s6sr25sc
Back to Search Results